Upregulation of TIM-3 in tumor cells that have become resistant to PD-1/PD-L1 blockade might be overcome by TIM-3 antibodies either administered alone or in combination with other immune checkpoint inhibitors [86]. The gene discussed is HAVCR2; the disease is neoplasm.